A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease.

Autor: Robinson EL; Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6229 ER Maastricht, The Netherlands., Gomes CPDC; Cardiovascular Research Unit, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg., Potočnjak I; Institute for clinical medical research and education, University Hospital Centre Sisters of Charity, Zagreb 10 000, Croatia., Hellemans J; Biogazelle, 9052 Zwijnaarde, Belgium., Betsou F; Integrated BioBank of Luxembourg, L-3555 Dudelange, Luxembourg., de Gonzalo-Calvo D; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, 25198 Lleida, Spain., Stoll M; Institute of Human Genetics, Genetic Epidemiology, University of Münster , 48149 Münster, Germany., Yilmaz MB; Department of Cardiology, Faculty of Medicine, Dokuz Eylül University, İzmir 35330, Turkey., Ágg B; Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1085 Budapest, Hungary.; Pharmahungary Group, H-6722 Szeged, Hungary., Beis D; Centre for Clinical, Experimental Surgery, & Translational Research, Biomedical Research Foundation, Academy of Athens, 115 27 Athens, Greece., Carmo-Fonseca M; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal., Enguita FJ; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal., Dogan S; Department of Medical Biology, School of Medicine, Yeditepe University, Istanbul 34755, Turkey., Tuna BG; Department of Biophysics, School of Medicine, Yeditepe University, Istanbul 34755, Turkey., Schroen B; Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, 6229 ER Maastricht, The Netherlands., Ammerlaan W; Integrated BioBank of Luxembourg, L-3555 Dudelange, Luxembourg., Kuster GM; Department of Biomedicine, University Hospital Basel and University of Basel, 4031 Basel, Switzerland., Carpusca I; Cardiovascular Research Unit, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg., Pedrazzini T; Department of Medicine, University of Lausanne Medical School, 1005 Lausanne, Switzerland., Emanueli C; National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK., Martelli F; Molecular Cardiology Laboratory, Policlinico San Donato IRCCS, San Donato Milanese, 20097 Milan, Italy., Devaux Y; Cardiovascular Research Unit, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.
Jazyk: angličtina
Zdroj: Non-coding RNA [Noncoding RNA] 2020 May 18; Vol. 6 (2). Date of Electronic Publication: 2020 May 18.
DOI: 10.3390/ncrna6020017
Abstrakt: The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1-4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.
Competing Interests: No potential conflict of interest was reported by any of the authors. If you are interested in learning more about the EU-CardioRNA COST Action or to apply to join a Working Group, please contact the corresponding authors.
Databáze: MEDLINE
Externí odkaz: